Cynata Therapeutics (ASX:CYP) - Managing Director & CEO, Dr Ross Macdonald
Managing Director & CEO, Dr Ross Macdonald
Sourced: Cynata Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Cynata Therapeutics (CYP) aims to raise $5.55 million to strengthen the company’s balance sheet
  • Cynata has already completed a $3.55 million placement but aims to raise a further $2 million in a share purchase placement
  • Funds will be used to progress clinical development to ensure Cynata is well placed to take advantage of further opportunities
  • Cynata is down 22.2 per cent in early afternoon trade and is selling shares for 65¢ each

Biotech company Cynata Therapeutics (CYP) aims to raise $5.55 million to strengthen the company’s balance sheet.

Cynata has successfully completed a $3.55 million placement to a small number of institutional investors. However, it aims to raise a further $2 million in a share purchase placement.

Placement

The company issued approximately 5.9 million new shares at a price of 60¢ per share. This represents a 23.3 per cent discount to the 15-day volume weighted average price to the closing share price as at April 17.

Settlement of the placement is expected to occur on April 23.

Share Purchase Plan (SPP)

Eligible shareholders will be able to apply for up to $30,000 worth of new shares at the same price as the placement.

Although there is a limit of $2 million under the SPP, the Board believes eligible shareholders may want to participate equitably in the overall capital raising and therefore exceeding the $2 million.

Funds

Funds from the placement and SPP will be used to progress clinical development, to ensure Cynata is well placed to take advantage of further opportunities and to strengthen the company’s balance sheet.

Chairman Paul Wotton says this is an uncertain time for investors, markets and companies as the COVID-19 pandemic continues to have an impact across the globe.

“Given the current market volatility and high degree of unpredictability in the economic outlook, the Board has made the decision to strengthen the Company’s balance sheet with a small capital raise designed to provide operational certainty at Cynata,” he said.

Cynata is down 22.2 per cent on the market in early afternoon trade and is selling shares for 65¢ each at 12:31 pm AEST.

CYP by the numbers
More From The Market Herald
Memphasys (ASX:MEM) - Managing Director & CEO, Alison Coutts

" Memphasys (ASX:MEM) launches $3.36m capital raising for Felix System commercialisation

Reproduction biotechnology and bio-separations company Memphasys (ASX:MEM) has launched a $3.36 million capital raising.
The Market Herald Video

" PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

Biotech company PharmAust (ASX:PAA) has reported "significant progress" on its canine cancer.

" MGC Pharmaceuticals (ASX:MXC) receives $1m ArtemiC order

MGC Pharmaceuticals (ASX:MXC) has received a US$1 million (A$1.43 million) order for its anti-inflammatory product, ArtemiC.
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.